1. Home
  2. SST vs VTGN Comparison

SST vs VTGN Comparison

Compare SST & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$2.34

Market Cap

12.9M

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.25

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SST
VTGN
Founded
2013
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
10.8M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
SST
VTGN
Price
$2.34
$0.25
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
562.9K
★ 18.9M
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $266,129,000.00
N/A
Revenue This Year
N/A
$33.96
Revenue Next Year
$21.02
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.35
$0.20
52 Week High
$8.19
$5.14

Technical Indicators

Market Signals
Indicator
SST
VTGN
Relative Strength Index (RSI) 41.27 45.13
Support Level $2.23 $0.22
Resistance Level $2.78 $0.67
Average True Range (ATR) 0.36 0.04
MACD -0.15 -0.00
Stochastic Oscillator 3.83 4.47

Price Performance

Historical Comparison
SST
VTGN

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: